Comparative evaluation of cellular damages and inflammatory responses between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Comparative evaluation of cellular damages and inflammatory responses between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation - Comparative evaluation between cryoballoon catheter ablation and radiofrequency catheter ablation for patients with atrial fibrillation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018461

Enrollment

100

Registered

2015-07-28

Start date

2015-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Interventions: Cryoballoon catheter group Arctic Front Advance or Freezor MAX cryoballoon catheter Control: radiofrequency catheter group NaviStar ThermoCool ablation catheter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Study subjects are atrial fibrillation patients (20-79 years old) who will undergo catheter ablation in University of Tsukuba Hospital, and give written informed consent for the study.

Exclusion criteria

Exclusion criteria: (1) severe LV dysfunction (LVEF < 35%) (2) severe mitral valve stenosis (3) severe atrial valve stenosis (4) open cardiac surgery within 3 months (5) percutaneous coronary intervention within 1 months (6) renal failure patients with hemodialysis (7) severe anemia (hemoglobin < 10g/dl in men, <9g/dl in women) (8) complicated with atrial flutter, supraventricular tachycardia, and ventricular tachycardia who are needed to undergo catheter ablation (9) patients who are likely to have poor prognosis such as terminal cancer (10) contraindication for catheter ablation (ex. left atrial appendage thrombosis)

Design outcomes

Primary

Measure	Time frame
Degree of cardiac injury (Troponin I)	—

Secondary

Measure	Time frame
The presence or absence of recurrence of atrial fibrillation during study periods. Time taken to treatment with catheter ablation. Components of Examination (CK, CK-MB, Troponin T, HFBP, vWF, thrombomodulin, P-selectin, Endothelin-1, WBC(Neutrophil), CRP, Serum amyloid A, E-selectin, PTX3, sCD40L, ferritin, IL-6, IL-8, TNF-alpha, TGF-beta, IL-4, IL-10, GDF15, D-dimer, TAT, PIC, HANP, BNP, NT Pro-BNP, MDA-LDL, 8-OHdG, MMP-2, TIMP-2, s-FasL)	—

Measure

Time frame

The presence or absence of recurrence of atrial fibrillation during study periods. Time taken to treatment with catheter ablation. Components of Examination (CK, CK-MB, Troponin T, HFBP, vWF, thrombomodulin, P-selectin, Endothelin-1, WBC(Neutrophil), CRP, Serum amyloid A, E-selectin, PTX3, sCD40L, ferritin, IL-6, IL-8, TNF-alpha, TGF-beta, IL-4, IL-10, GDF15, D-dimer, TAT, PIC, HANP, BNP, NT Pro-BNP, MDA-LDL, 8-OHdG, MMP-2, TIMP-2, s-FasL)

—

Countries

Japan

Contacts

Public ContactNobuyuki Murakoshi

University of Tsukuba Cardiovascular Division, Faculty of Medicine

n.murakoshi@md.tsukuba.ac.jp029-853-3142

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026